IMS Health Argentina provides market intelligence services to many of the top pharmaceutical companies worldwide, and is the benchmark company in this field. IMS Health Argentina has been present in the country for 35 years, and offers both data packages and consulting services for its clients.
One of the key aspects of the services that IMS Health Argentina provides are its regional services. Many of the multinational companies, and some national companies, use these services in order to gain critical insight into the Argentinean market in a regional context. IMS Health Argentina is in an excellent position to offer these services, as IMS Health is present throughout the region and has a team of experts dedicated to providing the best data possible.
Products and services
Patient-Centered Analytics, Pharma Commercial Services, Payer Solutions, Healthcare Outcomes, Specialty Analytics, Pharma R&D Services, Government Solutions, Business Process Outsourcing
Contact info:
IMS Health Argentina
Av. Leandro N. Alem 1050, 7° Piso
Buenos Aires, C1001AAS, Argentina
Teléfono: +54.11.4510.9700 fax: +54.11.4510.9797
Web: http://www.imshealth.com/portal/site/ims
Kalin Tochev, country manager of IQVIA Bulgaria, discusses the main trends taking place in the Bulgarian pharmaceutical sector and highlights the end-to-end approach that IQVIA offers to its clients to…
Jack Daly, Commercial Manager at IMS Health Ireland, discusses the strategic decision of IMS Health to diversify into the health consultancy space, the importance of developing long-term partnerships with clients…
Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its position as the partner of choice for decision-makers throughout the…
The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much…
Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last…
In part II of an exclusive interview at the eyeforpharma Barcelona Summit 2016, IMS Health’s Chief Digital Officer Richie Etwaru lifts the lid on the concept of Orchestrated Customer Engagement (OCE) and…
A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through…
IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his…
IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014,…
The general manager of IMS Health Argentina – South Cone weighs in on why his organization plays a crucial role in the pharma industry in Argentina. How does the Argentinean…
The general manager of the leading information solutions provider for the pharmaceutical and healthcare industry talks about the challenges Mexican patients face in the public sector, how large pharmacy chains…
IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also…
IMS’ General Manager, Maciej Kuzmierkiewicz, discusses the effects of the Reimbursement Act—the new legislative framework implemented in January 2012—which completely reshaped the rules of the game for the Polish pharmaceutical sector…
Al Z. Castro, General Manager of IMS Health Philippines, speaks about the ongoing challenges of bringing about awareness and acceptance of generics medicine to the local population, how this will…
Tom Rönnlund discusses the current state of the pharmaceutical industry in the Nordics in this time of austerity, and offers opinions on reference pricing and cooperation in the region. How…
Alex Ho has more than 15 years of significant pharmaceutical industry expertise, spanning across sales, marketing and product management in multinational companies. These companies include Novartis, Janssen, L’Oreal, GSK and…
Mr. Egan, what path led you to IMS Health? My original background is in science—I received a PhD in medical microbiology, and worked for some time as a post-doctoral researcher…
What attracted you to IMS Health? I was most attracted by the fact that IMS is able to actually change healthcare systems. I think IMS is a very important player…
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a…
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
IMS was recently acquired by two investment funds, how has this affected the operations of the company and what changes did it bring in the Chilean context? So far, the…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
It’s safe to assume that everywhere that IMS Health is established, there’s also a flourishing pharmaceutical industry. Could you give us an overview of Argentina’s IMS operations? IMS has been…
Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
IMS ‘lives and breathes the pharma industry’ and it is stimulating to come from other forms of consultancy to IMS. You have worked in various businesses. What motivated you to…
IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market?…
You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In 2007 you left to…
You worked as a Country Manager in Indonesia and Thailand prior to joining IMS Health in the Philippines. What, in your opinion, sets this market apart? For starters, Indonesia is…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
The national coordinator of Plan Nacer and Plan Sumar – two social security programs to improve access to healthcare in Argentina – discusses universal coverage as a constitutional right, and the…
A senior director for Icon plc discusses Argentina’s strengths and weaknesses as a venue for clinical trials, the role the market plays in a global clinical trial strategy, and Icon’s…
Dr. Wanda Dobrzanski discusses Argentina’s potential and attractiveness as a clinical research environment and the biggest challenges facing local and global CROs in Argentina. How has political and popular…
Gador’s first general director from outside of the family discusses his mission, Gador’s key to success, and his method for successfully leading a company in Argentina’s unpredictable and volatile market.…
The founder of Eriochem discusses his firm’s ambitious technology based on a competitive IP strategy and its exciting research on a radically new oncology platform. Today, Eriochem is a vertically…
The general manager of IMS Health Argentina – South Cone weighs in on why his organization plays a crucial role in the pharma industry in Argentina. How does the Argentinean…
Dr. Valverde, a respected authority on pharmacovigilance from the University of Mamonides, discusses the emerging pharmaceutical trade relationship between China and Argentina in the context of the dynamic Argentinian industry.…
Laboratorios Elea’s General Manager tells the story of the laboratories outstanding growth over the previous five years, the his firms upcoming launch of the first Argentinian developed biosimilar product. To…
The founder of Bomi Group’s affiliate in Argentina discusses the accomplishments of his firm thus far, and the challenges they have faced while trying to enter the very consolidated Argentinian…
Aegerion’s representative in Argentina discusses her efforts to raise awareness of Homozygous Familial Hypercholesteremia (HoFH), the rare disease targeted by her company’s ultra-orphan drug, and the remaining challenges of diagnosing…
Daniel Varde, Deloitte’s top consultant for the healthcare and life sciences sector in Latin America, discusses the interaction of global, Latin American, and Argentinian healthcare trends, and strategic techniques for…
See our Cookie Privacy Policy Here
